Related Experiment Video

Updated: Mar 19, 2026

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling
10:59

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling

Published on: May 19, 2014

18.9K

Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A

Regina Cencic1, Jerry Pelletier2

  • 1Department of Biochemistry, McGill University , Montreal, Québec, Canada.

Translation (Austin, Tex.)
|June 24, 2016
PubMed

Insights

Hippuristanol inhibits protein synthesis by targeting eukaryotic initiation factor 4A (eIF4A), a key step in cancer cell growth. This compound shows potential as an anti-cancer agent and validates eIF4A as a therapeutic target.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Protein synthesis is crucial for cancer development and progression.
  • Dysregulated translation control in cancer presents a potential therapeutic vulnerability.
  • Targeting translation initiation offers a strategy for novel anti-cancer drug development.

Purpose of the Study:

  • To investigate the biological properties of hippuristanol.
  • To evaluate hippuristanol's potential as an anti-cancer agent.
  • To validate eukaryotic initiation factor 4A (eIF4A) as a therapeutic target in cancer.

Main Methods:

  • Characterization of small molecule inhibitors targeting translation initiation.
  • Identification and study of hippuristanol, a polyhydroxysteroid from Isis hippuris.
  • Assay of hippuristanol's inhibitory effect on eIF4A RNA helicase activity.

Main Results:

  • Hippuristanol inhibits translation initiation by blocking eIF4A activity.
  • eIF4A is an essential RNA helicase involved in ribosome recruitment to mRNA.
  • Perturbed translation control in cancer cells can be exploited therapeutically.

Conclusions:

  • Hippuristanol demonstrates potential as an anti-neoplastic agent.
  • Targeting eIF4A represents a promising strategy for cancer therapy.
  • Further development of hippuristanol and similar compounds is warranted.
Keywords:
chemical biologyeIF4Ahippuristanoltranslational control

More Related Videos

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K
Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

6.9K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
14
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327